Blue Earth Diagnostics

About Blue Earth Diagnostics

Blue Earth Diagnostics, a Bracco company, specializes in the development and commercialization of molecular imaging agents for positron emission tomography (PET) imaging in the field of oncology. The company was established in 2014 by Sir Adrian Bodmer and Dr. Jonathan Allis. Dr. Allis, the founding CEO, brought extensive experience from his previous role as General Manager for PET at GE Healthcare’s Medical Diagnostics division, steering the company through its early stages and the development of its first product.

The company focuses on providing physicians with actionable information to improve patient management. Its business model centers on developing and commercializing these diagnostic agents, which are then used by hospitals and imaging centers. The primary market is oncology, with a specific focus on prostate and brain cancer. A significant milestone in the company's history was the acquisition of its first product, Axumin, from GE Healthcare. Subsequently, in 2019, Bracco Imaging S.p.A. acquired Blue Earth Diagnostics for $425 million, a move that provided substantial resources and global reach to accelerate its mission.

Blue Earth Diagnostics' portfolio is led by Axumin® (fluciclovine F 18), a PET imaging agent indicated for the detection of recurrent prostate cancer. Another key product is Cerianna™ (fluoroestradiol F 18), an estrogen receptor-targeting PET imaging agent used to detect recurrent or metastatic breast cancer. The company's pipeline includes investigational agents like 18F-fluciclovine, being explored for use in neuro-oncology, and POSLUMA® (flotufolastat F 18), an imaging agent designed to target Prostate-Specific Membrane Antigen (PSMA), which received FDA approval in May 2023 for PET imaging of prostate cancer.